CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

June 30, 2024

Conditions
Neutropenia, FebrileHematologic Cancer
Interventions
DRUG

Ceftolozane-tazobactam IV

Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.

Trial Locations (1)

Unknown

Hamad Medical Corporation, National Center for Cancer Care and Research, Doha

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Hamad Medical Corporation

INDUSTRY